II. Epidemiology
-
Prevalence
- Overall in U.S.: 5-10%
- Lifetime Prevalence: 10-22%
- Slightly more common in women (1.5 fold increased risk over men)
- Prevalence for elderly same as for young (however, peak time of diagnosis at 20-39 years old)
- Most common condition seen by Gastroenterologists
III. Pathophysiology
- Organic factors
- Gastrointestinal Hypersensitivity
- Altered motility
- Neurohormonal factors
- Mucosal barrier dysfunction
- Provoked by psychosocial risk factors
- Prior physical or sexual abuse significantly increases risk
- Severe Gastroenteritis episode may be associated (Odds Ratio 5.9)
- Antibiotics (Rifaximin, Neomycin) have reduced symptoms in some cases
- Familial association
- Risk increases 3 fold with Family History of Irritable Bowel Syndrome
IV. Associated Conditions
- Gastroesophageal Reflux Disease
- Dysphagia
- Globus Hystericus
- Fatigue
- Non-cardiac Chest Pain
- Urologic dysfunction
- Gynecologic disease (e.g. Chronic Pelvic Pain)
- Fibromyalgia
- Chronic Fatigue Syndrome
- Temperomandibular joint syndrome
- Food Allergy
- Low-fiber diet
V. Risk Factors: Psychosocial
- Anxiety Disorder
- Major Depression
- Somatization Disorder
- Sexual abuse or physical abuse
- Stressful life events
- Substance Abuse
VI. Types
- Alternating Diarrhea and Constipation
- Nervous Diarrhea
- Predominant Constipation
- Upper Abdominal Bloating and discomfort
VII. Symptoms
- Altered bowel habits
- Diarrhea
- Constipation
- Scybalous stools (hard, pellet-like stools)
- Mucus per Rectum (40% of cases)
- Incomplete evacuation Sensation (69% of cases)
- Recurrent and Chronic Abdominal Pain (73% of cases)
- Upper abdominal discomfort after eating
- Left Lower Quadrant Abdominal Pain
- Right Lower Quadrant Abdominal Pain
- Abdominal Pain relieved with Defecation (52% of cases)
- Gaseousness
- Excessive Flatulence or Eructation
- Normal patients experience about 13 farts per day
- Abdominal Distention (32% of cases)
- Nausea or Vomiting
- References
VIII. Exam
- Obtain a full set of Vital Signs including weight for comparison with historical weights
- Perform a general exam evaluating for undiagnosed systemic disease
- Perform a complete abdominal exam including genitourinary exam and Rectal Exam
IX. Diagnosis: Rome IV Criteria
- Abdominal symptoms persistent or recurrent for 6 months or more
- Symptoms occur at least one day per week for at least 3 months
- Abdominal Pain, bloating or discomfort
- Two or more below
- Related to Defecation (Straining, stool urgency, incomplete evacuation, pain relieved with stooling)
- Change in frequency of stool
- Change in appearance, form or consistency of stool
- Other symptoms supporting Irritable Bowel Syndrome diagnosis
- Abnormal stool frequency (>3/day or <3/week)
- Abnormal stool form (loose or watery, or hard and lumpy)
- Abnormal stool passage (urgency, straining, incomplete emptying)
- Mucus in stool
- Abdominal Distention or bloating (exclude red flag causes)
- Subtype classification
- Diarrhea predominant
- More than 25% of stools are Bristol Stool Scale 6-7 (Mushy or liquid stools) and less than 25% are type 1-2
- Constipation predominant
- More than 25% of stools are Bristol Stool Scale 1-2 (Hard or lumpy stool) and less than 25% are type 6-7
- Mixed
- More than 25% of stools are Bristol Stool Scale 6-7 (Mushy or liquid stools)
- More than 25% of stools are Bristol Stool Scale 1-2 (Hard or lumpy stool)
- Diarrhea predominant
- Changes from Rome III Criteria
- Altered stool passage criteria removed (Straining, stool urgency, incomplete evacuation)
- Rome IV requires weekly symptoms (previously monthly symptoms with Rome III)
- References
X. Diagnosis: Manning Criteria
- Onset of pain linked to more frequent Bowel Movements
- Looser stools associated with onset of pain
- Pain relieved by stool passage
- Noticeable Abdominal Bloating
- Sensation of incomplete evacuation more than 25% of the time
- Diarrhea with mucus more than 25% of the time
XI. Red Flags: Symptoms and signs suggestive of other diagnosis
- Red Flag Symptoms
- Nighttime Diarrhea
- Nocturnal Stool Incontinence
- Nocturnal awakening due to abdominal discomfort
- Abdominal Pain that interferes with normal sleep
- Diarrhea without pain suggests alternative diagnosis
- Severe large volume Diarrhea (esp. bloody, nocturnal, or unrelated to eating)
- Tenesmus
- Red Flag Signs
- Visible or occult blood in stool
- Unintentional Weight Loss
- Recurrent Fever
- Abdominal mass
- Jaundice
- Lymphadenopathy
- Red Flag Risk Factors
- Family History of Colon Cancer
- Family History of Inflammatory Bowel Disease
- Family History or other risk factors for Ovarian Cancer
- Older patients with new onset after age 55 years old
- Red Flag Laboratory abnormality
- Leukocytosis
- Anemia
- Increased Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein
XII. Differential Diagnosis
- Colonic Adenocarcinoma (Colon Cancer)
- Inflammatory Bowel Disease
- Abdominal Angina (Ischemic Colitis or Mesenteric Ischemia)
- Pseudo-obstruction (Diabetes Mellitus, Scleroderma)
- Intermittent Sigmoid Volvulus
- Endocrine causes
- Hypothyroidism or Hyperthyroidism
- Diabetes Mellitus
- Addison's Disease
- Electrolyte abnormalities associated with Constipation (Hypokalemia, Hypomagnesemia)
- Malabsorption
- Celiac Sprue (strongly consider if Diarrhea with red flags)
- Lactose Intolerance
- Pancreatic insufficiency
- Infectious Causes
- Giardiasis
- Clostridium difficile (Pseudomembranous colitis)
- Toxic Megacolon or Bacterial overgrowth syndrome
- Genitourinary Causes
- Other Functional Gastrointestinal Disorders
- Dyssynergic Defecation (Pelvic Floor Dysfunction)
- Functional Abdominal Bloating
- Functional Diarrhea
- Psychiatric illness (provocative)
- Medications
XIII. Evaluation
-
General
- Avoid a piecemeal work-up
- Perform a complete evaluation, based on presenting symptoms, the first time
- Avoid over-investigation and exhaustive testing
- Irritable bowel is no longer diagnosis of exclusion
- Diagnostic criteria above are sufficient to treat
- Lab and imaging are typically low yield in cases otherwise suggestive of Irritable Bowel Syndrome
- Fewer than 5% of Irritable Bowel Syndrome patients receive an alternative diagnosis
- El Serag (2004) Alminent Pharmacol Ther 19(8): 861-70 [PubMed]
- Indications for full evaluation and Gastroenterology
- Red flags present (see above) or
- Onset over age 50-55 years
- Avoid a piecemeal work-up
- Careful History
- History of Gastrointestinal Symptoms
- Family History of gastrointestinal disease
- Marital History
- Sexual Abuse (strong correlation)
- Reasonable exam
- Thorough abdominal examination
- Also focus on possible endocrine causes
- Look for Food Intolerance (consider diet diary)
XIV. Labs: Initial, based on predominant symptom
-
Constipation Dominant
- Complete Blood Count (CBC)
- Serum Electrolytes or Chemistry panel (chem8) including Serum Calcium
- Thyroid Stimulating Hormone (TSH)
- Digital Rectal Exam for rectal mass, impaction
- Other tests to consider
- Anorectal manometry (dyssynergic Defecation)
- Colon transit study (slow transit Constipation)
-
Diarrhea Dominant
- See Chronic Diarrhea
- See Chronic Watery Diarrhea
- Distinguish from non-allergic food intolerance (e.g. Lactose), Bile Acid Malabsorption
- Distinguish from chronic Functional Diarrhea (>25% loose stools without pain or bloating)
- Evaluation in absence of negative red flags
- Complete Blood Count (CBC)
- Celiac Sprue testing (esp. if signs of Iron Deficiency)
- IgA Tissue Transglutaminase AND
- Total IgA (with reflex if low to IgG Gliadin)
- Other tests to consider if indicated by history (previously recommended as part of standard default protocol)
- Fecal Calprotectin
- Stool GiardiaAntigen
- Stool Ova and Parasites
- Fecal Leukocytes
- Stool 48 hour collection for bile acid (evaluation for bile acid Diarrhea)
- Serum Electrolytes or chemistry panel
- Thyroid Stimulating Hormone (TSH)
- Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (C-RP)
- Colonoscopy with biopsy (see below)
- Pain Dominant
- Complete Blood Count (CBC)
- Reference
XV. Diagnostics
-
Colonoscopy of Flexible Sigmoidoscopy
- More uncomfortable in Irritable Bowel Syndrome
- Not absolutely indicated if remainder of evaluation suggests Irritable Bowel Syndrome
- Consider if red flags, age over 50 years or Microscopic Colitis risk
- Consider additional studies as indicated (to evaluate differential diagnosis)
- CT Abdomen with contrast
- Right upper quadrant Ultrasound
- Upper GI Study
- Barium Enema
XVI. Management: General Measures
- See the patient frequently
- Maintain a strong doctor-patient relationship
- Offer frequent reassurance of Irritable Bowel Syndrome as a benign condition
- Identify and treat emotional stressors
- Answer patients questions in unhurried environment
- Patient should keep a journal of symptoms combined with dietary intake and other triggers
- Do not downplay symptoms as psychiatric
- Irritable Bowel is a real functional bowel problem
- Explain physiology and absence of serious illness
- Reduce stressors
- Teach Relaxation Techniques
- Teach coping mechanisms for chronic illness
- Regular Daily Exercise
- Consider Probiotics (weak evidence)
- May improve bloating, Flatulence, pain and Constipation
- Bifidobacterium infantis (Align)
- Bifidobacterium bifidum MIMBb75
- Decreases overall irritable bowel symptoms
- Guglielmetti (2011) Aliment Pharmacol Ther 33(10): 1123-32 [PubMed]
-
General Diet recommendations
- Get adequate fluid intake (>64 ounces/day)
- Bulk agents
- See Fiber Supplementation
- Gradually increase to 25-30 g daily (and ensure adequate hydration)
- Risk of gas, bloating, distention, Flatulence if started too quickly with high dosing
- Side effects more likely with dyssynergic Defecation
- Side effects are more common with insoluble fiber
- Soluble Fiber Sources (absorbs water)
- Psyillium (Metamucil)
- Oat bran
- Insoluble Fiber Sources
- Methylcellulose (Citrucel)
- High fiber-bran, wheat brain
- Avoid FODMAPs (Fementable Oligo- di and mono saccharides and polyols)
- See FODMAP
- FODMAP avoidance may reduce pain, bloating, distention and overall bowel-related symptoms
- Considered a first-line intervention, and appears more effective than antispasmodics
- Black (2022) Gut 71(6): 1117-26 [PubMed]
- Carbone (2022) Gut 71(11): 2226-32 [PubMed]
- Avoid fructose (e.g. apples, pears, high fructose corn syrup)
- Avoid Fructans (fructooligosaccharides, inulins, levans - e.g. high fiber bars)
- Avoid Lactose (consider challenge with quart of skim milk)
- Avoid Polyols (sugar Alcohols: Sorbitol, xylitol, Mannitol, malitol
- Avoid Galactooligosaccharides (e.g. brussel sprouts, onions)
- Consider avoiding other provocative agents
- Consider Elimination Diet (although no evidence to support this)
- True food intolerance is a rare cause of symptoms
- FODMAPS restriction has much higher yielf
- Avoid Caffeine
- Avoid Alcohol
- Avoid Legumes and other gas producing foods (see FODMAPS above)
- Avoid Artificial Sweeteners and carbonated beverages (see Polyols above)
- Avoid Fatty meals
- Corn, wheat and citrus may also exacerbate Irritable Bowel Syndrome
- Some fiber can also exacerbate symptoms
- Consider Elimination Diet (although no evidence to support this)
- Avoid Provocative or addictive medications
- See Medication Causes of Diarrhea
- See Medication Causes of Constipation
- Avoid Stimulant Laxatives (except brief use)
- Avoid Sedatives or Tranquilizers (Benzodiazepines)
- Avoid Opioids
- Avoid Anticholinergic Medications such as Antihistamines (Constipation dominant IBS)
- Other medications that may contribute to Irritable Bowel Syndrome symptoms
- Antibiotics
- Calcium Channel Blockers
- Metformin
- Magnesium containing Antacids
XVII. Management: Diarrhea Dominant Irritable Bowel Syndrome
-
General measures (see above)
- Consider eliminating lactose, Caffeine from diet
- Exclude Gluten Sensitive Enteropathy as cause
- Fiber supplementation
- Probiotics
- Consider dietician Consultation
- Avoid provocative medications
-
Rifaximin (Xifaxan)
- Small improvements in symptoms (NNT 10) at a high cost ($1300 for a 14 day course)
- Relapse by 6 months is common (requiring another dose)
-
Eluxadoline (Viberzi)
- Schedule IV OpioidAgonist similar to Imodium, but taken daily at $1400/month
- Marginal efficacy (NNT 11) for decreased Diarrhea and Abdominal Pain at 6 months
- Risk of serious Pancreatitis (deaths have occurred) due to sphincter of odi spasm
- Contraindicated in prior Cholecystectomy, prior Pancreatitis or >3 Alcohol drinks per day
- (2016) Presc Lett 23(6):32
- (2017) Presc Lett 24(5):27
-
Alosetron (Lotronex)
- Like Ondansetron, also a Serotonin (5-HT3) receptor Antagonist that reduces rapid transit and stool urgency
- Risk of Constipation and Ischemic Colitis
- Iatrogenic deaths have occured
- Black box warning: Signed Informed Consent needed
- FDA controlled prescriptions only for women with IBS with Diarrhea
- Requires special Informed Consent and must be part of a prescriber program
- Dose: 0.5 mg orally twice daily (may advance to 1 mg twice daily after 4 weeks if tolerated)
-
Cholestyramine 4 grams at bedtime to 6 times daily
- Limited evidence
- Consider empiric trial (bile acid Diarrhea)
-
Loperamide (Imodium) 2-4 mg up to four times daily
- Before meals and as needed in stressful social situations
- Lomotil could be used, but has not been studied in IBS.
-
Ondansetron (Zofran)
- Ondansetron 4 mg up to three times daily (typically once daily or less)
- Serotonin (5-HT3) receptor Antagonist
- Reduces rapid transit and stool urgency and frequency
-
Amitriptyline (Elavil)
- Amitriptyline 10 mg titrated to 30-50 mg at bedtime (increasing dose by 10 mg per 1-2 weeks)
- Consider for pain and Diarrhea (Anticholinergic effects may reduce stooling)
- Peppermint
- Enteric coated Peppermint Oil (e.g. Pepogest)
- Pittler (1998) Am J Gastroenterol 93:1131-5 [PubMed]
XVIII. Management: Pain Dominant Irritable Bowel Syndrome
-
General measures (see above)
- Exercise
- Cognitive Behavioral Therapy
- Pain management
-
Chronic Pain
-
Tricyclic Antidepressants
- Amitriptyline (Elavil) 25 mg orally at bedtime
- Desipramine (Norpramin) 50 mg orally three times daily
- SNRI agents (e.g. Venlafaxine, Duloxetine) may be considered, but have not been definitively studied in IBS
- Tegaserod (Zelnorm)
- Withdrawn from market in 2007 due to Cardiovascular Risks (but still available for limited use)
- Nyhlin (2004) Scand J Gastroenterol 39:119-26 [PubMed]
- SSRI medications do not appear to be effective in reducing IBS symptoms including pain
-
Tricyclic Antidepressants
- Post-prandial pain: Anticholinergic
- Avoid chronic, frequent use
- Trial for 2 weeks and stop if no effect
- Antispasmodics
- Dicyclomine (Bentyl) 10-20 mg, 15-30 min before meal, up to 4 times daily
- Hyoscamine XR (Levbid) 0.375 to 0.75 mg twice daily (up to 1.5 g/day)
- Hyoscyamine (Levsin) 0.125 to 0.25 mg, 15-30 min before meal, up to every 4 hours (max 1.5 mg/day)
- Peppermint Oil (see reference below)
- Enteric coated Peppermint Oil (e.g. Pepogest)
XIX. Management: Constipation Dominant Irritable Bowel Syndrome
-
General measures (see above)
- Exercise
- Use gastro-colic response
- Wake-up, eat breakfast and anticipate stool in AM
- Avoid provocative medications
- First line: Bulk agents (e.g. Fiber, Psyllium, bran)
- Titrate to 20-30 grams per day
- Risk of bloating initially (requires adequate hydration)
- Evidence to support is lacking, but remains a central tool in IBS management
- Second line (use at bedtime for AM stool)
- Improves stool frequency, but may not alter Abdominal Pain or bloating
- Osmotic agents
- Polyethylene Glycol (Miralax) 1 capful in 8 ounces at bedtime (preferred)
- Lactulose 1-2 teaspoons at bedtime
- Milk of Magnesia 1-2 tablespoons at bedtime
- Consider Stimulant Laxatives if osmotic agents fail
- Third line (typically by gastrointestinal specialist referral)
- Prescription agents that increase gastrointestinal transit and intestinal fluid
- Expensive (even generic Amitiza is $300 per month)
- Linzess (Linaclotide)
- Guanylate cyclase-c Agonist
- May improve stool frequency, consistency, Abdominal Pain and straining, but risk of Diarrhea
- Expensive ($7 per pill) for minimal efficacy (NNT 5-8) for decreased pain
- (2012) Prescr Lett 19(12): 68-9
- Trulance (Plecanatide)
- Guanylate cyclase-c Agonist similar to Linzess (Linaclotide)
- Ibsrela (Tenapanor)
- Sodium/Hydrogen Exchanger 3 Inhibitor (NHE3 Inhibitor)
- Taken 50 mg orally twice daily immediately before first meal of day and then again in the evening
- Expensive ($1500/month in 2022 for twice daily dosing; other third line agents are $300 to $500/month)
- Increases intestinal fluid with similar efficacy as Lubiprostone and Linaclotide
- Risk of Diarrhea (16% of cases) which may be severe (2.5% of cases)
- (2022) Presc Lett 29(6): 36
- Curtis (2022) Am Fam Physician 105(6): 656-8 [PubMed]
- Prescription agents that increase gastrointestinal transit and intestinal fluid
- Restricted Use agent (emergency use only due to risk)
- Other agents potentially useful
- Amitiza (Lubiprostone)
- Acts at intestinal chloride channels to increase intestinal fluid secretion and Small Intestine stool transit
- Drossman (2009) Aliment Pharmacol Ther 29(3): 329-41 [PubMed]
- Loxiglumide (Cholecystokinin-A receptor Antagonist)
- Guar-Gum
- Peppermint
- Enteric coated Peppermint Oil (e.g. Pepogest)
- Pittler (1998) Am J Gastroenterol 93:1131-5 [PubMed]
- Amitiza (Lubiprostone)
XX. Management: Other specific symptoms or comorbidities
- Excessive Flatus (gas)
- See General dietary recommendations (including FODMAP avoidance) as above
- Simethicone 40 to 125 mg up to qid
- Beta-galactosidase (Beano)
- Comorbid Mood Disorders
- Major Depression
- SSRI Medications or other Antidepressants
- Anxiety
- Major Depression
XXI. Resources
- International Foundation for Functional GI Disorders
- American College of Gastroenterology
XXII. References
- (2015) Presc Lett 22(5):29
- Burgers (2020) Am Fam Physician 101(8): 472-80 [PubMed]
- Camilleri (2000) Gastroenterology 120:652-68 [PubMed]
- Camilleri (1999) Am J Med 107(5A):27F-32S [PubMed]
- Chang (2006) Curr Treat Options Gastroenterol 9(4):314-23 [PubMed]
- Drossman (1999) Am J Med 107(5A):41S-50S [PubMed]
- Hammer (1999) Am J Med 107(5A):5S-11S [PubMed]
- Heymann-Monnikes (2000) Am J Gastroenterol 95:981-4 [PubMed]
- Holten (2003) Am Fam Physician 67(10):2157-62 [PubMed]
- Jailwala (2000) Ann Intern Med 133:136-47 [PubMed]
- Mertz (2003) N Engl J Med 349:2136-46 [PubMed]
- Naliboff (1999) Curr Rev Pain 3:144-52 [PubMed]
- Ringel (2001) Annu Rev Med 52:319-38 [PubMed]
- Viera (2002) Am Fam Physician 66:1867-80 [PubMed]
- Weinberg (2014) Gastroenterology 147(5):1146-8 +PMID:25224526 [PubMed]
- Wilkins (2012) Am Fam Physician 86(5): 419-26 [PubMed]
- Wilkinson (2021) Am Fam Physician 103(12): 727-36 [PubMed]